Skip to main content
HANALL BIOPHARMA CO.,LTD logo

HANALL BIOPHARMA CO.,LTD — Investor Relations & Filings

Ticker · 009420 ISIN · KR7009420001 KO Manufacturing
Open in API
Filings indexed 336 across all filing types
Latest filing 2025-03-24 Transaction in Own Shar…
Country KR South Korea
Listing KO 009420

About HANALL BIOPHARMA CO.,LTD

http://www.hanallbiopharma.com/

HanAll Biopharma is a global biopharmaceutical company focused on developing innovative, first-in-class therapies for patients with unmet medical needs. The company's research and development efforts are centered on immunology, ophthalmology, and immuno-oncology, with a specialization in antibody-based therapeutics. Its pipeline includes novel treatments for autoimmune diseases and dry eye disease. The company's mission is to pioneer cutting-edge medicines that address incurable and immune-associated conditions. Alongside its innovative pipeline, HanAll Biopharma also operates a portfolio of pharmaceutical products in therapeutic areas including endocrine, circulatory, and urologic diseases.

Recent filings

Filing Released Lang Actions
주요사항보고서(자기주식취득결정)
Transaction in Own Shares Classification · 100% confidence The document is a formal regulatory filing titled '주요사항보고서(자기주식 취득 결정)' which translates to 'Major Report (Decision on Treasury Stock Acquisition)'. It details the company's decision to buy back its own shares, including the purpose, quantity, and financial limits. This falls directly under the category of 'Transaction in Own Shares' (POS).
2025-03-24 Korean
투자판단관련주요경영사항
Regulatory Filings Classification · 100% confidence The document is a formal regulatory filing from HanAll Biopharma submitted to the Korea Exchange (KRX). It details the 'Top-line results' of a Phase 3 clinical trial for the drug Batoclimab. This type of disclosure, which reports significant business developments or material events (such as clinical trial outcomes) to the public and regulators, is classified as a Regulatory Filing (RNS) in our system, as it serves as a formal announcement of material information rather than a full financial report or a simple publication notice.
2025-03-20 Korean
투자판단관련주요경영사항
Legal Proceedings Report Classification · 100% confidence The document is a formal regulatory filing from HanAll Biopharma regarding the initiation of arbitration proceedings with Harbour BioMed over a license agreement. It details legal disputes, arbitration parties, and the company's response strategy. Since this pertains to a significant legal/regulatory dispute and does not fit into specific categories like M&A or financial reporting, it is classified as a Legal Proceedings Report (LTR).
2025-03-18 Korean
사업보고서 (2024.12)
Annual Report Classification · 100% confidence The document is a 'Business Report' (사업보고서) for HanAll Biopharma Co., Ltd. for the fiscal year 2024 (Jan 1, 2024 - Dec 31, 2025). It contains comprehensive financial statements, management discussion and analysis, governance details, and auditor information. In the context of South Korean regulatory filings (DART), the 'Business Report' (사업보고서) is the equivalent of the US 10-K annual report, as it is the primary annual disclosure document containing full financial and operational data. FY 2024
2025-03-18 Korean
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a regulatory filing from HanAll Biopharma titled 'Audit Report Submission' (감사보고서 제출). It provides the audit opinion (unqualified/proper) and key financial data (assets, liabilities, revenue, profit/loss) for the fiscal year ending 2024-12-31. While it contains financial data, it is a formal regulatory disclosure of the audit report's receipt and findings rather than the full Annual Report (10-K) or a standalone audit report document. Given the structure and the nature of the filing as a mandatory regulatory disclosure of audit results, it fits best under the 'Audit Report / Information' category. FY 2024
2025-03-06 Korean
주요사항보고서(자기주식처분결정)
Transaction in Own Shares Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) filed with the Korean Financial Supervisory Service/Korea Exchange regarding a 'Decision to Dispose of Treasury Shares' (자기주식 처분 결정). This filing specifically details the company's plan to sell or transfer its own shares, which falls under the category of 'Transaction in Own Shares' (POS).
2025-02-25 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.